Page 1188 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPTEr 84 Immunoglobulin Therapy: Replacement and Immunomodulation 1153

41. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin complement-mediated neuronal cell death. Proc Nat Acad Sci
therapy for streptococcal toxic shock syndrome—a comparative 2007;104:14104–9.
observational study. Clin Infect Dis 1999;28:800–7. 55. Ephrem A, Chamat S, Miquel C, et al. Expansion of CD4+CD25+
42. Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in regulatory T cells by intravenous immunoglobulin: a critical factor in
rheumatic diseases. Nat Rev Rheumatol 2011;7:349–59. controlling experimental autoimmune encephalomyelitis. Blood 2008;111:
43. Tha-In T, Bayry J, Metselaar HJ, et al. Modulation of the cellular immune 715–22.
system by intravenous immunoglobulin. Trends Immunol 2008;29: 56. Othy S, Hegde P, Topcu S, et al. Intravenous gammaglobulin inhibits
608–15. encephalitogenic potential of pathogenic T cells and interferes with their
44. Ballow M. The IgG molecule as a biological immune response trafficking to the central nervous system, implicating sphingosine-1
modifier:mechanisms of action of intravenous immune serum globulin phosphate receptor 1-mammalian target of rapamycin axis. J Immunol
in autoimmuen and inflammatory disorders. J Allergy Clin Immunol 2013;190(9):4535–41.
2011;127:315–23. 57. Othy S, Topcu S, Saha C, et al. Sialylation may be dispensable for
45. Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. reciprocal modulation of helper T cells by intravenous immunoglobulin.
N Engl J Med 2008;359:307–9. Eur J Immunol 2014.
46. St-Amour I, Laroche A, Bazin R, et al. Activation of cryptic IgG reactive 58. Trinath J, Hegde P, Sharma M, et al. Intravenous immunoglobulin
with BAFF, amyloid beta peptide and GM-CSF during the industrial expands regulatory T cells via induction of cyclo-oxygenase-2-dependent
fractionation of human plasma into therapeutic intravenous prostaglandin E2 in human dendritic cells. Blood 2013;122(8):1419–27.
immunoglobulins. Clin immunol 2009;133:52–60. 59. Kaufman GN, Massoud AH, Audusseau S, et al. Intravenous
47. Vassilev TL, Kazatchkine MD, Van Huyen J-PD, et al. Inhibition of immunoglobulin attenuates airway hyperresponsiveness in a murine
cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal model of allergic asthma. Clin Exp Immunol 2011;41(5):718–28.
immunoglobulin for therapeutic use. Blood 1999;11:3624–31. 60. Massoud AH, Guay J, Shalaby KH, et al. Intravenous immunoglobulin
48. Gill V, Doig C, Knight D, et al. Targeting adhesion molecules as a attenuates airway inflammation through induction of forkhead box
potential mechanism of action for intravenous immunoglobulin. protein 3-positive regulatory T cells. J Allergy Clin Immunol 2012;129(6):
Circulation 2005;112:2031–9. 1656–65 e3.
49. Chang J, Shi PA, Chiang EY, et al. Intravenous immunoglobulins reverse 61. Massoud AH, Yona M, Xue D, et al. Dendritic cell immunoreceptor: a
acute vaso-occlusive crises in sickle cell mice through rapid inhibition of novel receptor for intravenous immunoglobulin mediates induction of
neutrophil adhesion. Blood 2008;111:915–23. regulatory T cells. J Allergy Clin Immunol 2014;133(3):853–63 e5.
50. Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome 62. Maddur MS, Vani J, Hegde P, et al. Inhibition of differentiation,
and toxic epidermal necrolysis: a review of the literature. Ann Allergy amplification, and function of human TH17 cells by intravenous
Asthma Immunol 2005;94:419–36. immunoglobulin. J Allergy Clin Immunol 2011;127(3):823–30 e1-7.
51. Viard I, Wehrli P, Bullanim R, et al. Inhibition of toxic epidermal 63. Olivito B, Taddio A, Simonini G, et al. Defective FoxP3 expression in
necrolysis by blockade of CD95 with human intravenous patients with acute Kawasaki disease and restoration by intravenous
immunoglobulin. Science 1998;282:490–3. immunoglobulin therapy. Clin Exp Rheumatol 2010;28(Suppl. 57):
52. Lunemann J, Nimmerjahn F, Dalakas MC. Intravenous imunoglobulin 93–7.
in neurology-mode of action and clinical efficacy. Nat Rev Neurol 64. Tsurikisawa N, Saito H, Oshikata C, et al. High dose intravenous
2015;11(2):80–9. immunoglobulin treatment increases regulatory T cells in patients with
53. Basta M. Modulation of complement-mediated immune damage by eosinophilic granulomatosis with polyangiitis. J Rheumatol 2012;39:
intravenous immune globulin. Clin Exp Immunol 1996;104(Suppl. 1): 1019–25.
21–5. 65. Ballow M. Mechanisms of immune regulation by IVIG. Curr Opin
54. Arumugam TV, Tang S, Lathia JD, et al. Intravenous immunoglobulin Allergy Clin Immunol 2014;14:509–15.
protects the brain against experimental stroke by preventing